HOOKIPA Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

HOOKIPA Pharma şirketinin toplam hissedar öz sermayesi $71.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $109.7M ve $37.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$59.75m
Eşitlik	US$71.80m
Toplam yükümlülükler	US$37.93m
Toplam varlıklar	US$109.73m

Son finansal sağlık güncellemeleri

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Nov 19

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26

Recent updates

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

Dec 21

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Nov 19

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

Sep 27

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Aug 13

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

Jun 22

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts

May 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: HOOK 'nin kısa vadeli varlıkları ( $93.2M ) kısa vadeli yükümlülüklerini ( $28.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: HOOK şirketinin kısa vadeli varlıkları ( $93.2M ) uzun vadeli yükümlülüklerini ( $9.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: HOOK borçsuzdur.

Borcun Azaltılması: HOOK şirketinin 5 yıl önce borç/öz sermaye oranı 3.8% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: HOOK şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: HOOK un, serbest nakit akışı her yıl % 11.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/06 20:39
Gün Sonu Hisse Fiyatı	2025/01/06 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

HOOKIPA Pharma Inc. 11 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alec Stranahan	BofA Global Research
Yu He	H.C. Wainwright & Co.
Swayampakula Ramakanth	H.C. Wainwright & Co.

HOOKIPA Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

HOOKIPA Pharma Provides Non-Compliance Update

HOOKIPA Pharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

HOOKIPA Pharma Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

Recent updates

Poolbeg Pharma PLC (AIM:POLB) entered into non-binding discussions to acquire HOOKIPA Pharma Inc. (NasdaqCM:HOOK) for $1.3 million in a reverse merger transaction.

Consensus EPS estimates fall by 57%

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

New major risk - Revenue and earnings growth

Price target decreased by 11% to US$38.75

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Doses First Patients with Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

Price target increased by 16% to US$43.50

Less than half of directors are independent

HOOKIPA Pharma Inc. Announces Board Changes

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Second quarter 2024 earnings: Revenues miss analyst expectations

HOOKIPA Pharma Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Consensus estimates of losses per share improve by 18%

Price target increased by 8.7% to US$50.00

HOOKIPA Pharma Inc. Announces CFO Changes

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting

First quarter 2024 earnings released: EPS: US$0.11 (vs US$0.27 loss in 1Q 2023)

HOOKIPA Pharma Inc. to Report Q1, 2024 Results on May 09, 2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

HOOKIPA Pharma Inc., Annual General Meeting, Jun 17, 2024

HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Inc. Announces FDA Clearance of Its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

HOOKIPA Pharma Inc. Announces European Medicines Agency Grant Prime Designation for the Investigational Product HB-200

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

HOOKIPA Pharma Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

HOOKIPA Pharma Provides Non-Compliance Update

Price target decreased by 11% to US$4.17

HOOKIPA Pharma Inc. Announces the Appointment of Mark Winderlich as Chief Development Officer, Effective April 1, 2024

HOOKIPA Pharma Inc. Announces Appointment of Dr. Roman Necina as Chief Operations Officer, Effective January 1, 2024

Hookipa Pharma Announces FDA Clearance of Its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Consensus revenue estimates increase by 14%

Price target decreased by 7.6% to US$4.32

HOOKIPA Pharma Inc. Presents Positive Biomarker and Translational Data on HB-200 Monotherapy At Society for Immunotherapy of Cancer 2023

HOOKIPA Pharma Inc. to Report Q3, 2023 Results on Nov 09, 2023

Hookipa Pharma Inc. Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

HOOKIPA Pharma Inc. Announces Resignation of Christine Baker as Chief Operating Officer, Leaving on January 15, 2024

HOOKIPA Pharma Inc. Announces Management Changes

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

Price target increased by 16% to US$5.38

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

HOOKIPA Pharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates upgraded to US$1.09 loss

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

HOOKIPA Pharma Inc. to Report Q1, 2023 Results on May 11, 2023

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Less than half of directors are independent

Price target decreased by 18% to US$4.64

Full year 2022 earnings: EPS and revenues exceed analyst expectations

HOOKIPA Pharma Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

HOOKIPA Pharma Appoints Katia Schlienger as Chief Medical Officer and Malte Peters to Board of Directors

Price target decreased to US$5.64

Consensus forecasts updated

Price target increased to US$7.17

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HOOKIPA Pharma Inc. to Report Q3, 2022 Results on Nov 14, 2022

Price target decreased to US$6.29